The first demonstration, in mice, of the idea that became SQ3370: a material placed beside a tumour switches on a doxorubicin prodrug given into the blood.
Shasqi's founder and collaborators present an approach they name local drug activation: bioorthogonal chemistry is used to concentrate and activate a systemic small molecule at a chosen place. The method does not depend on cellular or environmental markers, only on a biomaterial implanted beforehand near the site. In mice carrying xenografts of HT1080, a soft tissue sarcoma line, a doxorubicin prodrug activated this way gave a clear therapeutic benefit over systemic therapy with minimal side effects.
This is the origin of the approach, published four years before the first patient was treated.
Shares Shasqi, SQ3370, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, SQ3370, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, SQ3370, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, SQ3370, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, SQ3370, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares SQ3370, Click-activated prodrugs (bioorthogonal drug activation in the body).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/